Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides.
infoOramed Pharmaceuticals is a micro cap stock with a total market cap of 136.26M.
infoThey trade on the NASDAQ and had their IPO 16 years and 3 months ago.
infoOramed Pharmaceuticals currently employs 13 people.
infoAs of Wednesday, Aug 23 2023, Oramed Pharmaceuticals’s share price is $3.28.
News Relating to Oramed Pharmaceuticals
PennyStocks
Best Penny Stocks To Buy Today? 4 To Watch Under $5
Thursday May 04 2023 at 10:46
Penny stocks under $5 to watch this week. The post Best Penny Stocks To Buy Today?
The Motley Fool
Why Oramed Pharmaceuticals Stock Is Crashing Today
Thursday Jan 12 2023 at 11:50
The company’s lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes.
InvestorPlace
Why Is Oramed (ORMP) Stock Down 75% Today?
Thursday Jan 12 2023 at 10:44
Oramed (NASDAQ: ORMP ) stock is falling hard on Thursday after releasing data from a Phase 3 clinical trial. This clinical trial saw Oramed testing the efficiency of ORMD-0801 in patients with Type 2 Diabetes at 26 weeks against those taking a placebo.
Market Watch
Oramed’s oral insulin pill fails; stock is down 72%
Thursday Jan 12 2023 at 08:02
Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or secondary endpoints in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled trial compared Oramed’s treatment to placebo to see if it improved glycemic control in patients with type 2 diabetes.
Seeking Alpha
Oramed: NASH Biotech Play With Added Bonus
Wednesday Dec 07 2022 at 03:49
Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. Primary safety endpoint and secondary exploratory biomarker endpoints established proof of concept. Results from the phase 3 study using ORMD-0801 for the treatment of patients with Type 2 Diabetes are expected in January of 2023.
Seeking Alpha
Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Wednesday Sep 21 2022 at 05:52
Results from Oramed Pharmaceuticals’s first phase 3 study ORA-D-013-1, using ORMD-0801 for the treatment of patients with Type 2 Diabetes, is expected January 2023. Results from the ongoing Cohorts A and B, using Oravax for Covid-19, are going to be read out Q3 and Q4 of 2022 respectively.
The Motley Fool
Why Oramed Pharmaceuticals Stock Is On Fire Today
Tuesday Jul 12 2022 at 14:22
The biotech’s stock has been ripping higher of late.
The Motley Fool
Why Oramed Pharmaceuticals Stock Rocketed Higher Today
Friday Jul 08 2022 at 17:56
A reassuring letter to shareholders has the biotech’s stock jumping today.
Seeking Alpha
Oramed And Oral Insulin: Can This Small Company Really Do It?
Thursday Apr 14 2022 at 16:02
Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity.
Market Watch
Oramed’s Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh
Wednesday Dec 29 2021 at 06:14
Oramed Pharmaceuticals Inc. ORMP, -11.40% said Wednesday its Oravax Medical subsidiary has signed an agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Co. to pre-purchase 10 million doses of Oravax’s oral COVID-19 vaccines in development. The drug maker’s stock slipped 0.1% in premarket trading.
Seeking Alpha
Oramed: Prospects Still Remain Despite Merck-Ridgeback’s Progress
Monday Oct 04 2021 at 11:20
Giant pharma Merck’s co-developed oral coronavirus drug with Ridgeback Biotherapeutics has raised interest in non-injected vaccine alternatives.
InvestorPlace
7 Top-Rated Pharmaceutical Stocks To Invest in for October
Monday Oct 04 2021 at 10:01
It’s a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared first on InvestorPlace.
PRNewsWire
Oramed to Present at Canaccord Genuity’s 41st Annual Growth Conference
Monday Aug 09 2021 at 08:40
NEW YORK, Aug. 9, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Commercial Officer Michael Rabinowitz will present a company overview at Canaccord Genuity’s 41st Annual Growth Conference, held virtually this year from August 10-12, 2021. Mr.
Benzinga
Oramed Will Soon Start Clinical Trials For Oral COVID-19 Vaccine In Israel, Out licensed Injectable Version To Premas Biotech In India
Wednesday Jul 21 2021 at 11:44
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced several updates for its majority-owned company Oravax Medical Inc. Oravax is gearing up to commence clinical trials for its oral COVID-19 vaccine, first in Israel, then in additional clinical sites internationally.
PRNewsWire
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
Tuesday Jun 22 2021 at 08:40
NEW YORK, June 22, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 7, 2021, ranking them by total market capitalization.
PRNewsWire
Oramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine
Tuesday May 25 2021 at 08:40
NEW YORK, May 25, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Letter to Shareholders from Chief Executive Officer Nadav Kidron. Dear Shareholders, I’m excited to share with you significant milestones we have achieved over the past few months.
Seeking Alpha
Oramed Pharmaceuticals: Interesting Late-Stage Oral Insulin Developer
Sunday May 23 2021 at 18:09
Oramed Pharmaceuticals is developing an oral insulin in late clinical stages. Trial data has been positive, and the market potential is huge.
PRNewsWire
Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners’ Grand Rounds: A Webinar in Biotech and Specialty Pharma
Wednesday Apr 21 2021 at 07:25
NEW YORK, April 21, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that CEO Nadav Kidron will be featured in a live webinar titled Grand Rounds: a Webinar in Biotech and Specialty Pharma hosted by James Molloy, Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals at Alliance Global Partners on Monday, April 26, 2021 at 11:00 Eastern. Mr.
PRNewsWire
Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA’s Approved Dual Concurrent Protocol
Tuesday Mar 23 2021 at 08:51
NEW YORK, March 23, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in its ORA-D-013-2 study, the second of two concurrent Phase 3 studies of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D). The studies are taking place under U.S. Food and Drug Administration (FDA) approved protocols to treat T2D patients who have inadequate glycemic control over a period of 6 to 12 months.
Pulse2
ORMP Stock Price Increased Over 40% Pre-Market: Why It Happened
Tuesday Mar 23 2021 at 05:09
The stock price of Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) increased by over 40% pre-market. This is why it happened.
Benzinga
Oramed Shares Gain On COVID-19 Vaccine Joint Venture Pact
Friday Mar 19 2021 at 09:34
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) has entered into definitive agreements to form a joint venture focused on developing oral COVID-19 vaccines. The new company, Oravax Medical Inc, will use Oramed’s proprietary POD oral delivery technology and Premas Biotech Pvt.
PRNewsWire
Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines
Friday Mar 19 2021 at 08:40
NEW YORK, March 19, 2021 /PRNewswire/ — Good candidate for protection against COVID variants due to triple antigen targeting Implications for potential ease of widescale distribution and administration anytime, anywhere for oral COVID-19 vaccine Efficacy following a single oral dose administration in preclinical study Clinical trial expected to commence Q2 2021 Watch video Successful expansion of Oramed’s POD™ oral delivery technology into the lucrative vaccine development market Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive agreements to form a joint venture focused on the development of novel oral COVID-19 vaccines. The new company, Oravax Medical Inc., is based on Oramed’s proprietary POD™ oral delivery technology and Premas Biotech Pvt.
PRNewsWire
Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
Thursday Jan 21 2021 at 08:25
NEW YORK, Jan. 21, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery, announced today that randomization of patients in its first Phase 3 study of its oral…
PRNewsWire
Oramed to Present at H.C. Wainwright BioConnect 2021 Conference
Thursday Jan 07 2021 at 08:40
NEW YORK, Jan. 7, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H….
PRNewsWire
Oramed Reports Positive First in Human Data from Oral Leptin Study
Wednesday Dec 23 2020 at 08:25
NEW YORK, Dec. 23, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today results from a proof-of-concept study approved by Israel’s…
PRNewsWire
Oramed Initiates Phase 2 NASH Trial of Oral Insulin
Wednesday Dec 02 2020 at 08:25
NEW YORK, Dec. 2, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in a global trial of its…
PRNewsWire
Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference
Wednesday Oct 28 2020 at 08:40
NEW YORK, Oct. 28, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it is presenting a poster at the 2020 American Association of…
Yahoo
How Much Is Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) CEO Getting Paid?
Tuesday Aug 11 2020 at 16:20
This article will reflect on the compensation paid to Nadav Kidron who has served as CEO of Oramed Pharmaceuticals…
https://www.thelincolnianonline.com
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Expected to Announce Quarterly Sales of $690,000.00
Sunday Aug 09 2020 at 23:36
Wall Street brokerages expect Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) to announce $690,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Oramed Pharmaceuticals’ earnings, with the highest sales estimate coming in at $700,000.00 and the lowest estimate coming in at $680,000.00. Oramed Pharmaceuticals posted sales of $680,000.00 […]
businesswire
Global Hypertriglyceridemia Therapeutics Market to Generate Revenue of US$ 12,863.1 Million by end of 2027, Says Coherent Market Insights
Monday Jul 27 2020 at 00:00
The North America hypertriglyceridemia therapeutics market is estimated to be the most lucrative during the period of forecast.
Oramed Pharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Oramed Pharmaceuticals’s Altman Z-score is -11.94 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Oramed Pharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Oramed Pharmaceuticals.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Oramed Pharmaceuticals’s Income Quality of 0.88 is greater than its Industry Group of 0.69 (27.5% greater)
Oramed Pharmaceuticals’s Income Quality of 0.88 is greater than its Major Industry Group of 0.71 (23.9% greater)
Oramed Pharmaceuticals’s Income Quality of 0.88 is greater than its Sector of 0.75 (17.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Oramed Pharmaceuticals’s Current Ratio of 141.49 is greater than its Industry Group of 4.76 (2872.5% greater)
Oramed Pharmaceuticals’s Current Ratio of 141.49 is greater than its Major Industry Group of 4.32 (3175.2% greater)
Oramed Pharmaceuticals’s Current Ratio of 141.49 is greater than its Sector of 2.6 (5341.9% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-9.01 & -1.27)
Cannot compare a negative PE Ratio (-9.01 & -1.1)
Cannot compare a negative PE Ratio (-9.01 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cannot compare a negative PB Ratio (-432.57 & 1.34)
Cannot compare a negative PB Ratio (-432.57 & 1.4)
Cannot compare a negative PB Ratio (-432.57 & 1.62)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Oramed Pharmaceuticals’s ROE of 47.99 is greater than its Industry Group of -0.44 (11006.8% greater)
Oramed Pharmaceuticals’s ROE of 47.99 is greater than its Major Industry Group of -0.38 (12728.9% greater)
Oramed Pharmaceuticals’s ROE of 47.99 is greater than its Sector of -0.03 (160066.7% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Oramed Pharmaceuticals’s ROCE of -4.83 is lower than its Industry Group of -0.42 (-1050.0% lower)
Oramed Pharmaceuticals’s ROCE of -4.83 is lower than its Major Industry Group of -0.37 (-1205.4% lower)
Oramed Pharmaceuticals’s ROCE of -4.83 is lower than its Sector of -0.04 (-11975.0% lower)
Derived from SEC.GOV filing dataopen_in_new